The year ahead - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The year ahead
Some predictions about what's in store for contract services in 2010.


Pharmaceutical Technology Europe
Volume 22, Issue 1

The long view

Of course, making predictions about the future is a pretty futile business, and it is fortunate that people generally forget about predictions shortly after they are made. In fact, there are many factors that can affect the course of events in the near term and what looks to be a sure thing today can easily go awry tomorrow.

I recently watched an interview of the superstar investor Warren Buffett by the American journalist Charlie Rose. Commenting on the investment environment, Buffett made an observation that made a big impression. He said: "Things are always uncertain in the short term. What really is certain is that the things that worked over time will continue to work over time. So the next day is always uncertain. The next hour is always uncertain. The longer term is pretty darn certain."

As we look into the future of the pharmaceutical services industry, we can be certain about several things: that rising living standards and ageing populations will drive demand for healthcare; that drugs will continue to be a critical and costeffective part of the health care equation; and that discovery and invention will keep the pharmaceutical industry dynamic. Pharmaceutical services companies can be certain that the pharmaceutical industry will continue to offer new opportunities well into the future; their job will be to figure out how to exploit those opportunities.

Jim Miller is President of PharmSource and a member of Pharmaceutical Technology Europe's Editorial Advisory Board.

The author says...

• The factors that created problems in the pharmaceutical services industry in 2009 are expected to be carried into 2010, with new challenges on the horizon.

• Funding will remain uncertain for a large portion (small and mid-sized firms) of contract services clients, whilst the outcome of corporate reorganization within the pharmaceutical companies formed by the recent big mergers also creates uncertainty.

• Contract services companies will face stiffer competition in 2010 from large pharmaceutical firms that have increased their manufacturing capacity through mergers/acquisitions, as well as from each other as a number of service providers seek to expand their service offerings.

• Although the short-term future of contract services is unsettled, the pharmaceutical industry will continue to offer new opportunities for longterm growth.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here